Attached files
| file | filename |
|---|---|
| EX-31.2 - EX-31.2 - PLUS THERAPEUTICS, INC. | cytx-ex312_7.htm |
| EX-31.1 - EX-31.1 - PLUS THERAPEUTICS, INC. | cytx-ex311_14.htm |
| EX-23.1 - EX-23.1 - PLUS THERAPEUTICS, INC. | cytx-ex231_16.htm |
| EX-10.44 - EX-10.44 - PLUS THERAPEUTICS, INC. | cytx-ex1044_276.htm |
| EX-10.43 - EX-10.43 - PLUS THERAPEUTICS, INC. | cytx-ex1043_275.htm |
| EX-4.33 - EX-4.33 - PLUS THERAPEUTICS, INC. | cytx-ex433_277.htm |
| 10-K - 10-K - PLUS THERAPEUTICS, INC. | cytx-10k_20171231.htm |
EXHIBIT 32.1
CERTIFICATIONS PURSUANT TO 18 U.S.C. SECTION 1350/ SECURITIES EXCHANGE ACT RULE 13a-14(b), AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES – OXLEY ACT OF 2002
In connection with the Annual Report on Form 10-K of Cytori Therapeutics, Inc. for the year ended December 31, 2017 as filed with the Securities and Exchange Commission on March 9, 2018, (the “Report”), Marc H. Hedrick, as President & Chief Executive Officer of Cytori Therapeutics, Inc., and Tiago Girão, as VP of Finance and Chief Financial Officer of Cytori Therapeutics, Inc., each hereby certifies, respectively, that:
|
1. |
The Report fully complies with the requirements of Section 13(a) of the Securities Exchange Act of 1934. |
|
2. |
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Cytori Therapeutics, Inc. |
|
|
|
By: |
|
/s/ Marc H. Hedrick, MD |
|
Dated: March 9, 2018 |
|
|
|
Marc H. Hedrick, MD |
|
|
|
|
|
President & Chief Executive Officer |
|
|
|
|
|
|
|
|
|
By: |
|
/s/ Tiago M. Girão |
|
Dated: March 9, 2018 |
|
|
|
Tiago M. Girão |
|
|
|
|
|
VP of Finance and Chief Financial Officer |